Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting showing the performance of its Mercy Halo(tm) Ovarian Cancer screening test in a large cohort of asymptomatic, postmenopausal women. 

Read More